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Introduction
Therapeutic modalities that take advantage of effects of anti-
sense RNA molecules or the RNA interference pathway hold 
promise in the treatment of a wide range of conditions, includ-
ing cancer.1,2 However, numerous pitfalls and potential risks 
have been identified relating to the therapeutic administration 
of such agents.2 Primary among these is specificity, where 
off-target effects may induce adverse effects and immuno-
genicity could limit efficacy. As part of efforts to determine 
specificity, it is vital that a RNA therapeutic can be shown to 
reach its target, in the case of cancer, tumor cells, and act 
to deplete the factor it is directed against in vivo. For studies 
in patients with tumors at certain sites, the opportunities to 
obtain serial samples of such material are very limited, since 
unlike in animal studies, multiple biopsies and other invasive 
investigations are usually not possible. Consequently there is 
an urgent need to develop new approaches to assess target 
depletion by antisense RNA and related therapeutics.
Although methods exist, most notably immunohistochem-
istry, for determining protein depletion in a small population 
of solid tumor cells obtained by biopsy, or similar sampling 
techniques,3,4 these impose some significant limitations, prin-
cipally that only a limited number of cells can be analyzed 
and  the  data  obtained  is,  at  best,  semiquantitative.5–7  An 
alternative is quantitative real-time PCR based technology,8 
but some methods do not allow ready differentiation between 
tumor and nontumor cells in a biopsy or sample, or if PCR 
is performed on a dissected portion of tumor the signal from 
only a limited number of cells is considered.3,9 In addition, 
peripheral blood mononuclear cells are very commonly used 
as a surrogate in such analysis,10–17 but this is not informa-
tive regarding the relevant tumor-specific molecular target. 
  Perhaps  most  critically,  correlations  between  mRNA  and 
protein levels are often not strong.18–20 It is therefore clearly 
desirable to develop more quantitative methods to assess 
protein expression and its depletion in patient-derived mate-
rial using methods where tumor cells can be readily iden-
tified.  Flow  cytometric  (fluorescence-activated  cell  sorting 
(FACS))-based methods are ideal for this purpose, since tens 
of thousands of cells from each sampling can be analyzed 
and each expression signal directly quantified. Moreover, the 
multi-laser capacity of current FACS machines allows several 
tumor markers to be followed simultaneously (multiplexed).21
Survivin is a small (16.5 KDa) protein, originally identified 
as an inhibitor of apoptosis factor,22–24 existing as a homodi-
meric complex that is encoded by an essential gene.25,26 
There  is  an  increase  in  survivin  expression  at  mitosis,27 
and  survivin  depletion  has  been  associated  with  mitotic 
abnormalities.28–30 It is now clear that survivin is, in fact, 
both a bona fide inhibitor of apoptosis and also an impor-
tant mitotic progression factor.31,32 Importantly for the pres-
ent study, survivin is not detectable in most adult human 
tissues,  but  is  highly  expressed,  in  a  cell  cycle  phase-
independent  manner,  in  many  human  tumors.33 There  is 
evidence  that  this  disregulated  survivin  protein  acts  to 
decrease tumor susceptibility to apoptosis,34 and also to 
increase angiogenesis and resistance to several antican-
cer drugs.35,36 For these reasons, there is strong current 
interest in survivin inhibition and depletion as an anticancer 
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strategy, since survivin inactivation in human cells could 
increase  spontaneous  tumor-specific  apoptosis  and  also 
potentiate  the  action  of  other  antitumor  agents.32  In  this 
regard,  a  second  generation  18-mer  2′-O-methoxyethyl-
modified  antisense  oligonucleotide  (ASO)  (LY2181308) 
against  survivin  has  been  developed,  which  targets  the 
translation initiation codon of the survivin transcript, trig-
gering RNase-H–dependent duplex cleavage and subse-
quent transcript degradation.28 A first-in-human study has 
been initiated, and we report here a FACS-based strategy 
to directly quantify survivin protein and its depletion in non-
small cell lung cancer (NSCLC) tumor samples obtained 
from a patient treated with LY2181308.
Results
Proof-of-principle:  survivin  depletion  in  NSCLC  using 
cell lines
A well-characterized NSCLC cell line was initially evaluated for 
survivin protein levels, and for survivin depletion by the highly 
specific anti-survivin ASO LY2181308 (hereafter referred to 
as ASO).37 Figure 1a shows an anti-survivin immunoblot of 
whole-cell protein extracted from A549 NSCLC cells at 24 
and 72 hours following treatment with ASO, at increasing (and 
clinically relevant) doses from 0 to 40 nmol/l. It is clear that 
efficient depletion of survivin is achieved at 20 nmol/l ASO, 
and increasing the dose to 40 nmol/l does not significantly 
enhance depletion. Some depletion occurs by 24 hours, but 
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Figure 1  Effective survivin depletion can be achieved in NSCLC cell lines at pharmacologically relevant doses of ASO. (a) Up-
per panel, immunoblot of A549 cells treated with ASO for 24 or 72 hours. Lower panel, cell cycle distribution of treated cells, showing an 
increase in G2/M population, determined by propidium iodide staining and FACS analysis. (b) Treatment of A549 cells with increasing 
doses of ASO results in growth inhibition, data is the average of at least four repeats. (c) FACS analysis of 40 nmol/l ASO treated cells 
with PE-conjugated anti-survivin antibodies, and Alexa Fluor-647 conjugated serine-10 phospho-histone H3 antibodies. The percentage of 
cells falling in each quadrant is shown. (d,e) The data shown in c is quantified in these graphs, where the results shown are the average of 
four repeats and error bars show the standard error. ASO, antisense oligonucleotide; FACS, fluorescence-activated cell sorting; NSCLC, 
non-small cell lung cancer; PE, phycoerythrin.www.moleculartherapy.org/mtna
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is greater at 72 hours. Cells from this experiment were also 
fixed  and  stained  with  propidium  iodide  and  subjected  to 
FACS analysis (Figure 1a, lower panel). This revealed that 
treatment with 40 nmol/l ASO produced an enrichment of 
cells in the G2/M phase of the cell cycle, consistent with the 
known role for survivin in mitotic progression as a member of 
the chromosomal passenger complex.38 Moreover, survivin 
depletion by increasing doses of the ASO resulted in a dose-
dependent growth inhibition, again consistent with its role in 
mitotic progression (Figure 1b).
We next used a flow cytometry/FACS-based assay to ana-
lyze and quantify survivin levels in ASO-treated NSCLC cell 
lines. Briefly, cells were fixed with formaldehyde and immu-
nostained  for  survivin  and  the  serine-10  phosphorylated 
form of histone H3 (ser10pH3, a marker of mitotic progres-
sion). Consistent with results obtained by immunoblotting, 
FACS analysis revealed that following ASO treatment, the 
proportion of cells expressing survivin fell dramatically over 
the course of 72 hours, from ~90% to under 20% (Figure 1c 
and quantified in Figure 1d). We conclude that we can detect 
survivin expression in NSCLC cells by both immunoblot and 
by FACS analysis. We are also able to demonstrate efficient 
depletion of survivin by the ASO in NSCLC cell lines by both 
methods. We observed that ser10pH3 levels are reduced in 
NSCLC cell lines following survivin depletion, although only 
a small proportion of cells from these cultures express high 
levels ser10pH3 (Figure 1e). This  reduction  is  consistent 
with recent reports that survivin associates with aurora B 
to promote H3 phosphorylation at mitosis.39 It was there-
fore judged to be potentially valuable to include analysis of 
both survivin levels and ser10pH3 in the analysis of tumor 
samples, since clear changes in ser10pH3 levels would be 
a potentially informative additional marker of altered mitotic 
progression following survivin depletion.
Detection  of  survivin  protein  expression  in  human 
NSCLC tumor samples and normal lung tissue
To determine whether the FACS methodology used above 
could be adapted for the analysis of patient NSCLC tumor 
samples obtained by fiber optic-brushing techniques (FOB), 
we further developed this technique. The chief modifications 
and additions required to optimize the technique for use with 
patient FOB samples were: (i) development of methods to 
disaggregate the tumor material without introducing adven-
titious  cellular  damage;  and  (ii)  optimization  of  the  fixing 
conditions for co-staining with anti-survivin, anti-ser10pH3, 
and  DNA  (Hoescht  33258)  for  such  material.  Efficient 
tumor disaggregation was achieved using a “Medimachine” 
  (Becton-Dickinson, Oxford, UK) that gently grinds tissue into 
a single cell suspension, while introducing little adventitious 
damage,40 as confirmed by microscopy and FACS analysis 
assays for increased sub-G1 DNA content material and the 
induction of apoptosis (data not shown).
Pre-optimized fixing conditions were then applied to disag-
gregated FOB NSCLC tumor samples obtained from patients. 
In Figure 2a, the FACS profile demonstrates a distinct popu-
lation of cells expressing high levels of survivin, which are 
highlighted in red in Figure 2d. When survivin expression is 
plotted against ser10pH3, however, the cells cannot be fur-
ther stratified into distinct populations, reflecting the overall 
low expression of ser10pH3 (Figure 2b,e). Figure 2c shows 
the DNA content-profile of this sample, indicating that the 
majority of cells are in G0/G1 phase of the cell cycle, and in 
Figure 2f survivin expression is overlaid on this DNA con-
tent plot. This reveals that the distinct high (consistent with 
tumor) and low (consistent with normal) survivin-expressing 
populations also have slightly shifted G1 DNA content; with 
those cells expressing high survivin having a slightly greater 
DNA content than those with low survivin expression (see 
Supplementary Figure S1 for a description of how a nor-
mal G1 DNA content was ascribed to the samples). Since 
an increased DNA content (ploidy) is typical of tumor cells,41 
as is survivin expression,33 this data suggests that the two 
populations of cells detected in this patient are: cells with low 
survivin and low G1 DNA content are likely to be nontumor, 
and those with high survivin and greater G1 DNA content are 
likely to be tumor cells.
To further explore this point, we also obtained a FOB from 
the unaffected (contralateral) lung of a patient undergoing 
diagnostic FOB. In contrast to the tumor FOB sample, only 
a  single,  low  survivin-expressing  population  of  cells  was 
observed  (Figure  2g).  No  distinct  subpopulation  of  cells 
could be further identified by ser10pH3 staining (Figure 2h), 
and DNA staining revealed that the majority of these cells 
were in the G0/G1 phase of the cell cycle (Figure 2i).
In total, we have analyzed 36 NSCLC samples obtained by 
FOB, and the majority of them have a clearly detectable sur-
vivin positive population (with a median 30% survivin positive 
cells, red bars in Figure 2j). Of the two samples obtained 
from normal lung epithelia, FACS analysis did not reveal sur-
vivin expression markedly above the threshold of detection 
(1.0 and 1.6%, respectively, black bar in Figure 2j). In sum-
mary, cells obtained from normal bronchial epithelia by FOB 
can be readily distinguished from NSCLC samples due to 
the absence of survivin expression as determined by FACS 
analysis.
Note that, as part of our validation and clinical trial analysis, 
an unstained version of every sample also underwent FACS 
analysis (negative control). In addition, a control NSCLC cell 
line (NCI-H647) was stained with all antibodies and isotype 
negative controls to establish the threshold of detection on 
the FACS analyzer (see Supplementary Figure S2 for an 
example).
Analysis of survivin expression in FOB samples obtained 
from ASO-treated patients
Next, we analyzed a tumor sample from a patient enrolled 
in the first-in-human clinical trial of the anti-survivin ASO as 
a single agent in NSCLC. We sought to determine, using 
our FACS methodology, whether changes in tumor survivin 
expression could be detected following ASO administration.
FACS  analysis  for  survivin  expression  profiles  were 
obtained from FOB samples (taken from the same anatomi-
cal location) before (Figure 3a,b), and 48 hours after ASO 
administration (Figure 3d,e), with survivin alone plotted in 
Figure 3a,d, and survivin plotted against ser10pH3 in Figure 
3b,e. The data is quantified in Figure 3g. An 85% decrease 
in survivin expression is apparent following ASO treatment, 
where 14.5% of cells expressed high levels of survivin before 
treatment, but only 2.2% following treatment. Note that the Molecular Therapy–Nucleic Acids
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cell cycle profile of the sample does not radically alter fol-
lowing ASO treatment (Figure 3c,f). Taken together our data 
suggests that treatment with the ASO has depleted survivin 
in these tumor cells, or selectively eliminated high survivin-
expressing cells within the region of sampling. Regardless, 
this analysis indicates that we are able to detect changes in 
survivin expression profile in viable primary tumor material 
following its targeted depletion.
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Conventional  cytotoxic  chemotherapeutics  do  not 
deplete survivin
To further explore the specificity of survivin depletion following 
ASO administration, we also examined survivin expression in 
a patient treated with conventional cytotoxic chemotherapy 
(cisplatin-gemcitabine).  Tumor  FOB  samples  were  taken 
before (Figure 4a,b), and 48 hours following cisplatin-gem-
citabine administration (Figure 4d,e). However, and in con-
trast to the effects of survivin ASO treatment, survivin levels 
were only modestly decreased in the NSCLC FOB sample 
following  cisplatin  chemotherapy  (Figure  4g),  from  50.8% 
expressing high levels of survivin before treatment to 50.2% 
following treatment. There was some alteration in cell cycle 
profile in this sample following chemotherapy administration 
(Figure 4c,f), with a reduction in cells in G2/M phase, con-
sistent with the possibility that the treatment had impacted on 
the tumor cells and altered their cycling profile.
Discussion
We have developed a FACS-based approach for evaluating 
therapeutic protein depletion quantitatively in NSCLC tumor 
material obtained by FOB. Initially, we established the validity 
of FACS-based investigations in NSCLC cell lines, and then 
proceeded to analyze tumor material obtained by FOB from 
NSCLC patients. The parameters were selected to avoid intro-
ducing adventitious damage to the tumor material, because 
it was clear from pilot experiments that over-treatment in the 
disaggregation step, or over-fixation with formaldehyde, could 
have deleterious effects. The resulting methodology has some 
clear advantages over existing approaches (see Introduction). 
First, serial FOB sampling is relatively acceptable to patients.42 
Second, a sufficient quantity of tumor material can be obtained 
for the quantitative analysis of many thousands of cells by flow 
cytometry methods. Third, it is clear that very little adventitious 
cellular damage is sustained during the FOB procedure and 
subsequent tumor disaggregation, since we have now ana-
lyzed 50 NSCLC FOB samples the vast majority of which were 
of sufficiently high quality for FACS analysis and/or cell sorting 
(36 which is 72% of total FOB samples collected, see Figure 
2j). Although the conditions we selected appeared to be opti-
mal for NSCLC, we cannot be certain that these conditions 
would be appropriate for other tumor types.
Having  confirmed  that  FOB  coupled  to  disaggregation  is 
a robust method for obtaining samples that can be analyzed 
by FACS and cell sorting, we progressed to analysis of sur-
vivin expression in NSCLC tumor samples. Notably, survivin 
is expressed in almost all solid tumors, including NSCLC, but 
not normal adult tissue, making it an excellent tumor marker 
with broad applicability.32,33 Based upon this finding, we predict 
that survivin expression will be an excellent marker for other 
types of FACS-based clinical studies in NSCLC. For example, 
the expression of other key biomarkers under investigation in 
NSCLC can be evaluated in the survivin positive and nega-
tive cell populations obtained by FOB, transbronchial needle 
aspiration, endobronchial ultrasound sampling, and in circu-
lating tumor cells.43–46 This will permit direct quantification, at 
the protein level, of markers (for example XPF-ERCC1, EGFR, 
and K-ras in NSCLC) in patient tumors, and a direct means 
of comparing their expression in nontumor material obtained 
from the same anatomical location. Indeed, ongoing studies 
from our laboratory indicate that the methodology will be an 
effective way of determining XPF protein expression in NSCLC 
samples. We conclude that the basic methodology presented 
here,  and  identification  of  survivin  as  a  robust  marker  of 
NSCLC  tumor  cells,  will  be  a  powerful  tool  for  performing 
tumor-specific, quantifiable studies of multiple biomarkers in 
this disease.44
We then applied this FACS methodology to the analysis of 
FOB samples from a patient enrolled in a clinical trial of an 
anti-survivin  ASO. The  pharmacokinetic/pharmacodynamic 
model predicts that 750 mg dose of LY2181308 achieves an 
intratumoral concentration greater than EC50 (half maximal 
effective concentration) (20 μg/g) that is associated with a 
>50% survivin protein inhibition.47 Following ASO treatment 
the number of cells expressing the highest levels of survivin 
drastically reduced. The methodology developed here is cur-
rently being applied to samples from selected NSCLC patients 
enrolled in the phase 1 clinical trial of the LY2181308 ASO, 
and the summary data from this cohort of patients has been 
published elsewhere as part of the phase 1 trial report.47
In  summary,  we  have  developed  a  robust  approach  to 
quantitatively  assess  levels  of  survivin  protein  in  patient 
tumor samples derived by FOB. This method can be broadly 
applied to differentiate tumor from nontumor cells in serial 
samples from NSCLC patients. Moreover, the method pro-
vides a very powerful way of quantifying protein expression 
within the tumor and nontumor populations of a single sam-
ple obtained in clinical trials involving targeted agents such 
as the ASO presented here.
Materials and methods
Treatment  of  cell  lines  with  LY2181308.  Cells  were  trans-
fected with the stated doses of ASO LY2181308 (sequence: 
5′-TGTGCTATTCTGTGAATT-3′) dissolved in Lipofectamine 
Figure 2  Survivin expression and cell cycle profile in NSCLC and normal tissue FOB determined by FACS. (a) Tumor FOB sample, 
stained for survivin and ser10pH3, where survivin expression alone is plotted. (b) Tumor FOB sample, stained for survivin and ser10pH3, 
both markers plotted against one another. The percentage of cells falling in each quadrant is shown. (c) Cell cycle profile, obtained by 
Hoescht 33258 staining. (d) Analysis of survivin positive cells (red) versus negative (black) showing distinct population of positive cells col-
lected in the brushing material. (e) Analysis as in b, where the survivin positive population is highlighted in red. (f) Evidence that G1 peak 
represents two population, showing survivin positive (red) and negative cells (gray), as defined in b and e. Survivin negative cells have a 
slightly lower G1 DNA content than the survivin positive population. (g) Cell population obtained from FOB of normal bronchial epithelium. 
Analysis of survivin staining in normal cells demonstrates the presence of a single population of cells with low survivin expression. (h) 
These cells cannot be further stratified by plotting ser10pH3 expression against survivin expression. The percentage of cells falling in each 
quadrant is shown. (i) Cell cycle profile of FOB sample from normal bronchial epithelium. (j) Distribution of samples showing the percent-
age of survivin positive cells (defined as in e and h) for each sample. Thirty-six NSCLC samples were analyzed (red bars) and two normal 
bronchial epithelia samples were also obtained (black bars). FACS, fluorescence-activated cell sorting; FOB, fiber optic brushing; NSCLC, 
non-small cell lung cancer; PE, phycoerythrin; ser10pH3, serine-10 phosphorylated form of histone H3.Molecular Therapy–Nucleic Acids
Survivin Depletion in Tumors
Olsen et al
6
transfection reagent and OPTIMEM reduced-serum medium 
(Invitrogen,  Paisley,  UK).  This  second  generation  ASO 
contains  contains  2′-O-methoxyethyl  (2′-MOE)  residues 
(underlined)  within  a  phosphorothioate  backbone  and  the 
two cytosines (positions 5 and 10) are 5-methyl substituted. 
Media was removed from cultured cells, which were washed 
twice in serum-free medium, and then incubated in the ASO 
transfection mixture for 4 hours. After 4 hours, the transfec-
tion mixture was washed off, and cells were placed back into 
tissue culture media for the appropriate period.
Patient  selection  and  treatment.  For  the  analysis  of  pre-
treated  NSCLC  tumor  as  controls,  patients  undergoing 
diagnostic FOB as part of their routine care were invited to 
participate in the Oxford Radcliffe Thoracic Biobank study 
(Oxford  Research  Ethics  Committee  (OxREC)  approved 
study, reference: 09/H0606/5). Endobronchial brushings were 
sampled and processed immediately according to the meth-
ods described below. Patients with NSCLC participating in 
the first-in-human study of single agent LY2181308 (OxREC 
reference: 04/MRE02/52) gave informed signed consent to 
endobronchial tumor sampling by FOB before LY21813008 
treatment and at 48 hours after administration of 750 mg 
intravenously over 3 hours daily for 3 days. For evaluation of 
the effects of cytotoxic chemotherapy on apoptosis, cell cycle 
progression, and survivin protein expression in chemother-
apy naive patients, patients gave signed informed consent for 
pre-treatment and post-treatment endobronchial tumor sam-
pling 48 hours following the first cycle of cisplatin (80 mg/M2 
intravenous D1) and gemcitabine (1,250 mg/M2 D1) (OxREC 
reference: C00.082).
LY2181308 solution was supplied by Eli Lilly (Indianapo-
lis, IN) in glass vials with elastomeric closures containing 4.2 
ml of active study drug at a concentration of 25 mg/ml. The 
drug product formulation contained active LY2181308 and 
phosphate-buffered saline (PBS) at pH 7.2. The supply and 
preparation of gemcitabine and cisplatin followed standard 
operating procedures of the Oxford Radcliffe Hospitals Trust.
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Figure 3  Examination of survivin expression pre- and post-ASO treatment in a trial patient. (a) Survivin positive (red) and negative 
(black) populations defined by FACS, before ASO administration. (b) Survivin expression plotted against ser10pH3 expression, before 
(pre-) ASO administration. The percentage of cells falling in each quadrant is shown. (c) Cell cycle (DNA content) distribution shown by 
black line, survivin positive cells (as defined in b) overlaid in red. (d-f) As a-c, but for sample obtained 48 hours following (post-) ASO admin-
istration. (g) Quantification of fraction of high survivin-expressing cells pre- and 48 hours post-treatment. ASO, antisense oligonucleotide; 
FACS, fluorescence-activated cell sorting; PE, phycoerythrin; ser10pH3, serine-10 phosphorylated form of histone H3.www.moleculartherapy.org/mtna
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FOB. Fiber optic endobronchial tumor sampling is a safe, 
short, standard procedure used in the diagnosis of pulmo-
nary diseases. Patients who had provided informed, signed 
consent were lightly sedated, typically with intravenous mida-
zolam,  and  had  topical  anesthetic  applied  to  the  airways. 
Endobronchial tumors were sampled by brushing with a 1 
mm brush under endoscopic vision.
Tumor disaggregation. The cut FOB brush was placed into 
10 ml of cold PBS, and kept at 4 °C for duration of pro-
cessing. The brush in PBS was vortexed for 5 seconds at 
maximum speed. The brush was transferred to a fresh 10 ml 
aliquot of PBS, and the vortexing procedure repeated. The 
released material was pooled and pelleted by centrifugation 
1,000g for 5 minutes at 4 °C, and the pellet resuspended 
in 1.5 ml cold PBS. The sample was transferred into a 50 
mm “Medicon” disaggregation cell, and the unit placed in a 
“Medicon Medimachine” and subject to a 10 seconds pulse. 
The suspended sample was removed and the “Medicon” cell 
rinsed with PBS twice.
Controls for staining made by staining NCI-H647 NSCLC 
cells that were processed as described.48
Fixation of disaggregated tumor. The tumor cell suspension 
was concentrated by centrifugation at 1,000g for 5 minutes 
at 4 °C. The supernatent was removed, and the pellet was 
resuspended in 1% ice-cold formaldyhyde fixation buffer with 
gentle agitation. The sample was vortexed for 10 seconds 
and incubated at 4 °C for 24 hours.
Antibody and DNA staining of FOB sample. The fixative was 
removed by centrifigation at 1,000g for 5 minutes at 4 °C, 
followed by washing the pellet with cold PBS. The pellet was 
resuspended into 50 μl SAP buffer (0.1% (wt/vol) saponin, 
in Hank’s balanced salt solution) containing 5 mg/ml Hoe-
scht 33258. The sample was stained with 2 μl of Alexa fluor 
Figure 4 Treatment with cisplatin-gemcitabine did not strongly deplete survivin expression in a NSCLC tumor. (a) Survivin positive 
(red) and negative (black) populations defined by FACS, before cisplatin-gemcitabine chemotherapy administration. (b) Survivin expres-
sion plotted against ser10pH3 expression, before (pre-) cisplatin-gemcitabine chemotherapy administration. The percentage of cells falling 
in each quadrant is shown. (c) Cell cycle (DNA content) distribution, with survivin positive cells (as defined in b) overlaid in red. (d-f) As 
a-c, but for sample obtained 48 hours following (post-) cisplatin-gemcitabine administration. (g) Quantification of fraction of high survivin-
expressing cells pre- and 48 hours post-treatment. FACS, fluorescence-activated cell sorting; NSCLC, non-small cell lung cancer; PE, 
phycoerythrin; ser10pH3, serine-10 phosphorylated form of histone H3.
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  647-conjugated  anti-Histone  H3  pSer10  antibody  (Cell 
  Signaling 9716; Cell Signaling Technology, Hitchin, UK) and 
3 μl Phycoerythrin-conjugated anti-Survivin antibody (R&D 
Systems IC6472P; R&D Systems, Abingdon, UK). Compara-
ble quantities of antibodies were used to stain control cell line 
NIHC647. IgG isotype controls (the IgG isotype controls for 
these were phycoerythrin-conjugated mouse IgG (R&D Sys-
tems IC002P) and Alexa Fluor-conjugated rabbit IgG (Cell 
Signaling 3452), respectively) were included. Samples were 
mixed with gentle agitation and stored in dark for 60 minutes. 
Samples were pelleted at 1,000g for 5 minutes at 4 °C, and 
washed with 500 μl PBS containing 5 mg/ml Hoescht 33258, 
and then stored at 4 °C in dark.
FACS  analysis  and  cell  sorting.  FACS  analysis  was  per-
formed on a Cyan ADP Flow cytometer, and data analyzed 
using Summit version 4.3 (Becton Coulter, High Wycombe, 
UK) and Flowjo version 8 software (TreeStar, Ashland, OR).
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